Please provide your email address to receive an email when new articles are posted on . Baseline BMI may impact treatment effect of tirzepatide in patients with HFpEF and obesity. Distribution of ...

New research presented at this year’s European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12-15 May) and published in The Lancet shows that people who have lost weight using the maximum ...

In today’s fast-paced world, managing weight and metabolic health has become a crucial concern for many. With the rise of obesity and related health issues, effective solutions are in high demand.

Use of tirzepatide within the first 4 years of type 2 diabetes (T2D) diagnosis produced significant improvements in glycemic control, body weight, and cardiovascular risk factors compared to usual ...

Database study compares protective effect of new GLP-1-based drugs in cardiovascular risk patients Evident heart benefits beyond weight loss Only few differences in effectiveness between semaglutide ...

New research presented at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12–15 May) and published in The Lancet shows that people who have lost weight using the maximum tolerated ...

Mounjaro, a tirzepatide drug prescribed for diabetes, could help people without this condition lose 13% of their body weight in the space of 6 months. Image credit: Tatsiana Volkava/Getty Images. Over ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation ...

Eli Lilly and Company, along with partner institutions in the US and United Kingdom, describe how short-term pharmacologic intervention does not appear to have lasting effects for most tirzepatide ...

Tirzepatide and semaglutide would have to drop their current net prices by 30.5% and 81.9%, respectively, to be cost-effective. Over a lifetime of use, tirzepatide could avert 45,609 obesity cases, 20 ...